Edward Garon
MD, MS
Professor
University of California, Los Angeles

Edward Garon is the Director of the Thoracic Oncology Program at the David Geffen School of Medicine at UCLA and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently a Professor of Medicine. He also received a Master's degree in clinical investigation from UCLA. He has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Sessions

Register
General Session

Session 10: Debate: Front-Line c-MET or BRAF Mutations: TKIs vs Immunotherapy - DISCUSSION

Sunday, April 28, 2024
9:55 AM - 10:05 AM
General Session

Session 11: Debate: Should Liquid Biopsies Be Part of Initial Workup? - DISCUSSION

Sunday, April 28, 2024
10:55 AM - 11:05 AM
General Session

Session 12: Case Discussions

Sunday, April 28, 2024
11:05 AM - 11:45 AM
General Session

Session 13: Debate: Should Pemetrexed Be Continued in KEYNOTE-189? - NO

Sunday, April 28, 2024
12:45 PM - 1:00 PM
General Session

Session 13: Debate: Should Pemetrexed Be Continued in KEYNOTE-189? - DISCUSSION

Sunday, April 28, 2024
1:00 PM - 1:10 PM
General Session

Session 14: Debate: Oligoprogression or Oligo-remnant mNSCLC: Local Ablative Approaches Is Standard - DISCUSSION

Sunday, April 28, 2024
1:40 PM - 1:50 PM
General Session

Session 15: Debate: Is Docetaxel + Ramucirumab the Standard Second-Line? - YES

Sunday, April 28, 2024
1:50 PM - 2:05 PM
General Session

Session 15: Debate: Is Docetaxel + Ramucirumab the Standard Second-Line? - DISCUSSION

Sunday, April 28, 2024
2:20 PM - 2:30 PM
General Session

Welcome

Saturday, October 05, 2024
8:00 AM - 8:05 AM
General Session

Welcome

Sunday, October 06, 2024
8:30 AM - 8:35 AM